← Neo Corporate Pcl overview

Neo Corporate Pcl vs Specialty Natural Products PCL: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Neo Corporate Pcl (NEO.BK)

Q3 2026
▲2▼2

Neo Corp Q3: Stimulus Drives Record Sales, But Valuation and Q4 Risks Loom

  • Record Q3 sales and profit surge Thailand's Thai Chai Thai Plus stimulus scheme covering 40 million recipients is a major tailwind, with analysts expecting record Q3 sales of 3.2 billion baht and profit up 261–321%.

    This is the main positive force driving Neo's Q3 performance.

  • Margin support from cost cuts and partnerships Price hikes, falling palm kernel oil costs, and new BASF partnerships support margins and future growth.

    These factors improve profitability and strategic position.

  • Downgrade on valuation concerns After a 14% four-week rally, KGI downgraded NEO to hold, citing full valuation and priced-in Q3 results.

    This reflects a shift in analyst sentiment that could cap price gains.

  • Q4 profit may decline from Q3 peak Q4 profit may decline from Q3's peak due to flooding and new factory depreciation, limiting near-term upside.

    This introduces a potential headwind for the next quarter.

September 2026
▲3▼1

NEO's profit surge and stimulus lift targets, but valuation now looks full

  • Government stimulus drives record sales and profit Thailand's Thai Chai Thai Plus co-payment scheme, extended through November, is boosting NEO's sales because 92% of its revenue comes from domestic consumer products. Analysts expect record third-quarter sales of 3.2 billion baht and profit up 261-321% from a year earlier, as the scheme puts money in shoppers' hands.

    This is the main force behind NEO's earnings surge and repeated target price hikes.

  • Price increases and lower costs lift profit margins NEO raised prices on some products by 4-5% in July and targets a gross margin of 37-39%. A 7% month-on-month fall in palm kernel oil costs also helps. Analysts expect third-quarter gross margin around 38%, supporting profit growth even as sales rise.

    Margin expansion is a key reason profit is growing faster than sales.

  • New products and partnerships support future growth NEO is teaming up with BASF to develop personal care ingredients and is pushing its brands into lifestyle items for younger consumers through collaborations. These moves aim to keep sales growing after the stimulus ends, though their impact will take time to show.

    These initiatives address longer-term growth beyond the current stimulus boost.

  • Valuation looks full after strong run; one broker downgrades to hold NEO shares have risen about 14% in four weeks, and KGI downgraded the stock to hold, saying the market has already priced in the strong third-quarter results. Fourth-quarter profit may also fall from the third-quarter peak due to flooding and new factory depreciation. This limits near-term upside.

    It is the main counterweight: good news is already reflected in the price, so further gains may be limited.

Latest
▲3▼1

NEO's profit surge and stimulus lift targets, but valuation now looks full

  • Government stimulus drives record sales and profit Thailand's Thai Chai Thai Plus co-payment scheme, extended through November, is boosting NEO's sales because 92% of its revenue comes from domestic consumer products. Analysts expect record third-quarter sales of 3.2 billion baht and profit up 261-321% from a year earlier, as the scheme puts money in shoppers' hands.

    This is the main force behind NEO's earnings surge and repeated target price hikes.

  • Price increases and lower costs lift profit margins NEO raised prices on some products by 4-5% in July and targets a gross margin of 37-39%. A 7% month-on-month fall in palm kernel oil costs also helps. Analysts expect third-quarter gross margin around 38%, supporting profit growth even as sales rise.

    Margin expansion is a key reason profit is growing faster than sales.

  • New products and partnerships support future growth NEO is teaming up with BASF to develop personal care ingredients and is pushing its brands into lifestyle items for younger consumers through collaborations. These moves aim to keep sales growing after the stimulus ends, though their impact will take time to show.

    These initiatives address longer-term growth beyond the current stimulus boost.

  • Valuation looks full after strong run; one broker downgrades to hold NEO shares have risen about 14% in four weeks, and KGI downgraded the stock to hold, saying the market has already priced in the strong third-quarter results. Fourth-quarter profit may also fall from the third-quarter peak due to flooding and new factory depreciation. This limits near-term upside.

    It is the main counterweight: good news is already reflected in the price, so further gains may be limited.

August 2026
▲3

NEO's profit surge and stimulus extension keep growth story alive

  • Q2 profit jumps 161%, sales hit record NEO's second-quarter profit surged 161% to 209 million baht, with record sales of 3.05 billion baht, up 18% from a year earlier. The company raised its full-year sales growth target to double digits, showing strong momentum in household and personal care products.

    This is the core earnings event that shows the company's fundamental strength and supports the stock's value.

  • Government stimulus extension to boost Q4 demand Thailand's cabinet approved a two-month extension of the Thai Chai Thai Plus co-payment scheme, injecting up to 70 billion baht into the economy. NEO is named a top beneficiary because its consumer products are sold through traditional retail channels used by the program's 40 million recipients.

    This directly supports NEO's domestic sales and profit in the fourth quarter, a key driver of future earnings.

  • Brokers raise targets, see profit growth ahead Dao Securities maintains a Buy rating with a 31 baht target, expecting 2026 profit to grow 14% to 642 million baht. It notes the stock trades at only 11.2 times earnings, below its historical average, and does not yet reflect the profit recovery trend.

    Analyst upgrades and attractive valuation can draw investor attention and support the share price.

▲3

NEO's profit surge and stimulus extension keep growth story alive

  • Q2 profit jumps 161%, sales hit record NEO's second-quarter profit surged 161% to 209 million baht, with record sales of 3.05 billion baht, up 18% from a year earlier. The company raised its full-year sales growth target to double digits, showing strong momentum in household and personal care products.

    This is the core earnings event that shows the company's fundamental strength and supports the stock's value.

  • Government stimulus extension to boost Q4 demand Thailand's cabinet approved a two-month extension of the Thai Chai Thai Plus co-payment scheme, injecting up to 70 billion baht into the economy. NEO is named a top beneficiary because its consumer products are sold through traditional retail channels used by the program's 40 million recipients.

    This directly supports NEO's domestic sales and profit in the fourth quarter, a key driver of future earnings.

  • Brokers raise targets, see profit growth ahead Dao Securities maintains a Buy rating with a 31 baht target, expecting 2026 profit to grow 14% to 642 million baht. It notes the stock trades at only 11.2 times earnings, below its historical average, and does not yet reflect the profit recovery trend.

    Analyst upgrades and attractive valuation can draw investor attention and support the share price.

Specialty Natural Products PCL (SNPS.BK)

Q3 2026
▲3▼1

SNPS: weak Q2 margins, but Indonesia demand and new plant drive growth

  • Weak Q2 profit and broker downgrade SNPS's Q2 profit came in weak, with margin squeezed as extract costs rose with oil prices while selling prices stayed flat. Brokers cut the 2026 profit forecast and target price to 5 baht, downgrading the stock to TRADING. This weighs on the share price.

    This is the main negative force on the stock and explains the recent price weakness.

  • Indonesia orders and rainy-season cough demand SNPS sees clear growth in Indonesia, with natural colour orders expected to rise significantly by year-end. The rainy season is boosting partner sales of cough and lung care products that use its extracts. A weaker baht also lifts margins on overseas sales, supporting revenue growth.

    This is a new demand driver that supports future revenue and profit growth.

  • New Bang Phli plant on track for end-2026 SNPS is building a new plant in Bang Phli, due by end-2026, to make medicines and medical devices from herbal active ingredients. It targets 15-30% revenue growth this year and keeps a ~40% gross margin. Analysts expect H2 profit to recover to about 26 million baht per quarter.

    This shows a concrete expansion that could drive future sales and profit recovery.

  • Regulatory push and import-risk warning SNPS backs a Positive Lists health claims system to cut product development time and cost, helping its natural extracts business. Its CEO also warned that Thailand imports over 80% of drugs and 90% of key ingredients, urging faster local production. Both support the long-term case for SNPS.

    These policy and supply-chain themes could benefit SNPS's domestic production and product approvals over time.

August 2026
▲3▼1

SNPS: weak Q2 margins, but Indonesia demand and new plant drive growth

  • Weak Q2 profit and broker downgrade SNPS's Q2 profit came in weak, with margin squeezed as extract costs rose with oil prices while selling prices stayed flat. Brokers cut the 2026 profit forecast and target price to 5 baht, downgrading the stock to TRADING. This weighs on the share price.

    This is the main negative force on the stock and explains the recent price weakness.

  • Indonesia orders and rainy-season cough demand SNPS sees clear growth in Indonesia, with natural colour orders expected to rise significantly by year-end. The rainy season is boosting partner sales of cough and lung care products that use its extracts. A weaker baht also lifts margins on overseas sales, supporting revenue growth.

    This is a new demand driver that supports future revenue and profit growth.

  • New Bang Phli plant on track for end-2026 SNPS is building a new plant in Bang Phli, due by end-2026, to make medicines and medical devices from herbal active ingredients. It targets 15-30% revenue growth this year and keeps a ~40% gross margin. Analysts expect H2 profit to recover to about 26 million baht per quarter.

    This shows a concrete expansion that could drive future sales and profit recovery.

  • Regulatory push and import-risk warning SNPS backs a Positive Lists health claims system to cut product development time and cost, helping its natural extracts business. Its CEO also warned that Thailand imports over 80% of drugs and 90% of key ingredients, urging faster local production. Both support the long-term case for SNPS.

    These policy and supply-chain themes could benefit SNPS's domestic production and product approvals over time.

Latest
▲3▼1

SNPS: weak Q2 margins, but Indonesia demand and new plant drive growth

  • Weak Q2 profit and broker downgrade SNPS's Q2 profit came in weak, with margin squeezed as extract costs rose with oil prices while selling prices stayed flat. Brokers cut the 2026 profit forecast and target price to 5 baht, downgrading the stock to TRADING. This weighs on the share price.

    This is the main negative force on the stock and explains the recent price weakness.

  • Indonesia orders and rainy-season cough demand SNPS sees clear growth in Indonesia, with natural colour orders expected to rise significantly by year-end. The rainy season is boosting partner sales of cough and lung care products that use its extracts. A weaker baht also lifts margins on overseas sales, supporting revenue growth.

    This is a new demand driver that supports future revenue and profit growth.

  • New Bang Phli plant on track for end-2026 SNPS is building a new plant in Bang Phli, due by end-2026, to make medicines and medical devices from herbal active ingredients. It targets 15-30% revenue growth this year and keeps a ~40% gross margin. Analysts expect H2 profit to recover to about 26 million baht per quarter.

    This shows a concrete expansion that could drive future sales and profit recovery.

  • Regulatory push and import-risk warning SNPS backs a Positive Lists health claims system to cut product development time and cost, helping its natural extracts business. Its CEO also warned that Thailand imports over 80% of drugs and 90% of key ingredients, urging faster local production. Both support the long-term case for SNPS.

    These policy and supply-chain themes could benefit SNPS's domestic production and product approvals over time.